[Federal Register Volume 67, Number 153 (Thursday, August 8, 2002)]
[Notices]
[Pages 51584-51585]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-20039]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Various Retrovirus 
Isolated From Humans

AGENCY: Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209 (e)and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a worldwide exclusive 
license to practice the inventions embodied in the patents and patent 
applications referred to below to Antibody Systems, Inc., located in 
Hurst, Texas. The patent rights in these inventions have been assigned 
to the government of the United States of America. The patents and 
patent applications to be licensed are:
    Title: Retrovirus Isolated from Humans, U.S. Patent No. 5,882,912. 
Issue Date: 03/16/99. CDC Reference No. I-012-97/0; New Spumavirus 
Isolated form Humans, U.S. Patent Application PCT/US98/02598 dated 2/
12/98. CDC Reference No. I-012-97/1; Spumavirus

[[Page 51585]]

Isolated from Humans, U.S. Patent Application 09/367,213 dated 12/08/
1999. CDC Reference No. I-012-97/2; New Retrovirus Isolated from 
Humans, U.S. Patent Application PCT/US01/51411 dated 10.19.2001. CDC 
Reference No. I-023-00/0 Spumavirus Isolated from Humans, U.S. Patent 
Application PCT/US99/25171 dated 10/27/99. CDC Reference No. I-034-97/
0; Spumavirus Isolated from Humans, U.S. Patent Application Serial No. 
09/830,616 filed 9/05/01. CDC Reference No. I-034-97/1;
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
    These inventions cover unique spumavirus isolates and clones from 
infected humans, and an infectious spumavirus vector. Licensee will 
further development this technology to assess this vector's suitability 
for gene therapy applications, attenuated vaccines, and use as a stable 
replicating viral vector.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Andrew Watkins, Director, Technology Transfer 
Office, Centers for Disease Control and Prevention (CDC), 4770 Buford 
Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8600; 
facsimile: (770) 488-8615. Applications for a license filed in response 
to this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by CDC within sixty days of this notice will 
be considered. Comments and objections submitted in response to this 
notice will not be made available for public inspection, and, to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552. A signed Confidential Disclosure 
Agreement will be required to receive a copy of any pending patent 
application.

    Dated: August 2, 2002.
Joseph R. Carter,
Associate Director for Management and Operations, Centers for Disease 
Control and Prevention (CDC).
[FR Doc. 02-20039 Filed 8-7-02; 8:45 am]
BILLING CODE 4163-18-P